K
Katleen Callewaert
Researcher at Ragon Institute of MGH, MIT and Harvard
Publications - 7
Citations - 1244
Katleen Callewaert is an academic researcher from Ragon Institute of MGH, MIT and Harvard. The author has contributed to research in topics: Vaccination & Sofosbuvir. The author has an hindex of 6, co-authored 6 publications receiving 1122 citations. Previous affiliations of Katleen Callewaert include Janssen Pharmaceutica & Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz,Mark S. Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,John D. Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L Lindsay,Maria Beumont,Ira M. Jacobson +21 more
TL;DR: Combined simeprevir and sofosbuvir was efficacious and well tolerated in chronic HCV genotype 1 infections and sustained virological response 12 weeks after stopping treatment was achieved.
Journal ArticleDOI
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch,Dan H. Barouch,Frank Tomaka,Frank Wegmann,Daniel J. Stieh,Galit Alter,Merlin L. Robb,Merlin L. Robb,Nelson L. Michael,Lauren Peter,Joseph P. Nkolola,Erica N. Borducchi,Abishek Chandrashekar,David Jetton,Kathryn E. Stephenson,Kathryn E. Stephenson,Wenjun Li,Bette T. Korber,Georgia D. Tomaras,David C. Montefiori,Glenda Gray,Nicole Frahm,M. Juliana McElrath,Lindsey R. Baden,Jennifer Johnson,Julia Hutter,Edith Swann,Etienne Karita,Hannah Kibuuka,Juliet Mpendo,Nigel Garrett,Kathy Mngadi,Kundai Chinyenze,Frances Priddy,Erica Lazarus,Fatima Laher,Sorachai Nitayapan,Punnee Pitisuttithum,Stephan Bart,Thomas B. Campbell,Robert Feldman,Gregg Lucksinger,Caroline Borremans,Katleen Callewaert,Raphaele Roten,Jerald C. Sadoff,Lorenz Scheppler,Mo Weijtens,Karin Feddes-de Boer,Danielle van Manen,Jessica Vreugdenhil,Roland Zahn,Ludo Lavreys,Steven Nijs,Jeroen Tolboom,Jenny Hendriks,Zelda Euler,Maria G. Pau,Hanneke Schuitemaker +58 more
TL;DR: All vaccine regimens demonstrated favourable safety and tolerability and immunogenicity and protective efficacy against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3).
Journal Article
svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3
Ira M. Jacobson,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Mark S. Sulkowski,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L. Lindsay,M. Beumont-Mauviel,Eric Lawitz +20 more
Journal ArticleDOI
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lindsey R. Baden,Daniel J. Stieh,Michal Sarnecki,Stephen R. Walsh,Georgia D. Tomaras,James G. Kublin,M. Juliana McElrath,Galit Alter,Guido Ferrari,David C. Montefiori,Philipp Mann,Steven Nijs,Katleen Callewaert,Paul A. Goepfert,Srilatha Edupuganti,Etienne Karita,Johannes P. M. Langedijk,Frank Wegmann,Lawrence Corey,Maria G. Pau,Dan H. Barouch,Dan H. Barouch,Hanneke Schuitemaker,Frank Tomaka,Julie A Ake,Susan Buchbinder,Karen Buleza,Kristen W. Cohen,Trevor A Crowell,Zelda Euler,Ian Frank,Dimitri Goedhart,Michael C. Keefer,Colleen Kelly,Kenneth H. Mayer,Joseph P. Nkolola,Lauren Peter,Merlin L. Robb,Nadine Rouphael,Lorenz Scheppler,Magda Sobieszczyk,Hong Van Tieu +41 more
TL;DR: This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously tested trivalent formulation, which was found to elicit higher immune responses than the MITvalent regimen.
Journal ArticleDOI
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Lindsey R. Baden,Lindsey R. Baden,Lindsey R. Baden,Stephen R. Walsh,Stephen R. Walsh,Michael S. Seaman,Yehuda Z. Cohen,Jennifer Johnson,Jennifer Johnson,J. Humberto Licona,J. Humberto Licona,Rachel D Filter,Jane A. Kleinjan,Jon A Gothing,Julia Jennings,Lauren Peter,Joseph P. Nkolola,Peter Abbink,Erica N. Borducchi,Marinela Kirilova,Kathryn E. Stephenson,Kathryn E. Stephenson,Poonam Pegu,Poonam Pegu,Michael A. Eller,Michael A. Eller,Hung V. Trinh,Hung V. Trinh,Mangala Rao,Julie A Ake,Michal Sarnecki,Steven Nijs,Katleen Callewaert,Hanneke Schuitemaker,Jenny Hendriks,Maria G. Pau,Frank Tomaka,Bette T. Korber,Galit Alter,Galit Alter,Raphael Dolin,Raphael Dolin,Patricia L. Earl,Bernard Moss,Nelson L. Michael,Merlin L. Robb,Merlin L. Robb,Dan H. Barouch,Dan H. Barouch,Ipcavd +49 more
TL;DR: Both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants in the HIV-1 vaccine-naive group and env-specific responses were induced after a single immunization in nearly all subjects who had previously received the prototype Ad26.ENVA.01 vaccine.